Assessment of lung function after COVID-19 reported in the literature
| First author [ref.] | Patients, n | Time after discharge | FVC, % pred | TLC, % pred | FEV1, % pred | DLCO, % pred | Lung function abnormalities, n (%) | Low FVC <80% pred, n (%) | Low TLC <80% pred, n (%) | Low FEV1 <80% pred, n (%) | DLCO <70% pred, n (%) |
| Zhao [3] | 55 | 3 months | NA | NA | NA | NA | 14 (25.5) | 6 (10.9) | 4 (7.3) | NA | 9 (16.4) |
| Bellan [8] | 238 | 4 months | 98.5 (90–109) | NA | 101 (92–112) | 79 (69–89) | NA | NA | NA | NA | 113 (51.6) |
| González [15] | 62 | 3 months | 82±17 | 84±16 | 89±19 | 68±13 | NA | NA | 23 (37.1) | NA | 50 (82) |
| Lerum [10] | 103 | 3 months | 94 (76–121) | NA | 92 (84–106) | 83 (72–92) | NA | 7 (7) | NA | 11 (11) | 24 (24) |
| Shah [11] | 57 | 3 months | 94±16 | 86±13 | 93±16 | 77±16 | 33 (58) | NA | NA | NA | 30 (52) |
| Wu [2] | 83 | 3 months | 92 (81–99) | 87 (77–98) | 90 (76–100) | 77 (67–87) | NA | 19 (23) | 22 (27) | 25 (30) | 46 (55) |
| 6 months | 94 (85–104) | 91 (82–98) | 92 (80–101) | 76 (68–90) | NA | 13 (16) | 16 (19) | 20 (24) | 45 (54) | ||
| 12 months | 98 (89–109) | 91 (87–100) | 96 (85–110) | 88 (78–101) | NA | 9 (11) | 12 (15) | 13 (16) | 27 (33) | ||
| Sonnweber [151] | 145 | 2 months | NA | NA | NA | NA | 53 (42) | 34 (27) | 14 (11) | 28 (22) | 39 (31) |
| 4 months | NA | NA | NA | NA | 48 (36) | 29 (22) | 15 (11) | 30 (22) | 28 (21) | ||
| Qin [152] | 647 | 3 months | 90±13 | 99±24 | 94±11 | 83±25 | NA | 17 (21) | NA | 5 (6) | 31 (38) |
| Gamberini [153] | 178 | 12 months | 97±19 | NA | 100±17 | 78±22 | NA | NA | NA | NA | NA |
Pulmonary function test data are presented as median (interquartile range) or mean±sd. FVC: forced vital capacity; TLC: total lung capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; NA: not available.